On January 13, 2026, according to 3Dzyk, HuaqingZhimei (Shenzhen) Biotechnology Co., Ltd. (referred to as “Huamei BioTech”) recently completed a tens of millions of yuan Series A financing round. This round of financing was led by Leaguer Venture Capital, with Shaanxi Financial Control and Zijin Hongxin participating as co-investors. The funds raised will be used to advance the technological upgrading and large-scale production of biological 3D printing technology and human-engineered ECM (extracellular matrix) materials.

Huamei BioTech was founded by a team of doctoral students and faculty from Tsinghua University, specializing in the research and development of biological 3D printing technology and Extracellular Matrix (ECM). With its technological breakthroughs in the field of cell printing, the company has established a leading position in the industry worldwide.

The company’s core technologies encompass biological 3D printing, regenerative synthetic biology, and microfluidic technology, enabling the precise construction of bionic microenvironments to ensure high cell viability and stable production. Huamei BioTech has established the world’s first large-scale 3D printing production line for cell-grade materials and is conducting clinical research in multiple fields, including osteoarthritis, neural repair, and skin health.

In addition, Huamei BioTech actively promotes the standardization process within the industry. The company has taken the lead in participating in the formulation of China’s first ECM (Extracellular Matrix) group industry standard and is committed to accelerating the industrial application of related technologies.

This round of financing marks a significant step forward for Huamei BioTech in the fields of bioprinting and regenerative medicine, showcasing China’s technological innovation and industrialization capabilities in the biomanufacturing sector. With continuous breakthroughs in technology, Huamei BioTech is poised to maintain its leadership in advancing global bioprinting and the manufacturing of cell-grade materials.

Mr. Sui Jianfeng, General Manager of Shenzhen Leaguer Venture Capital, stated:

“We firmly invested in Huamei BioTech based on the core rationale of its irreplicable technological strengths: the 25-year-deep expertise that has created a formidable barrier in biological 3D printing technology, its globally leading capability for the large-scale preparation of human-derived ECM, and the strategic value of cell-grade materials as the next generation of regenerative materials. Biomanufacturing is a core track for future industries under the ’15th Five-Year Plan,’ and technological innovation is key to breaking through in this field. Leaguer Venture Capital will continue to provide comprehensive support—including capital, industry resources, and policy alignment—to assist Huamei BioTech in becoming a global technological benchmark in the cell-grade materials industry.”

Mr. Liu Chao, General Manager of Shaanxi New Era Capital, stated:

Huamei BioTech, centered on its core technological concept of a “multi-dimensional bionic cell growth microenvironment,” has tackled key technical challenges in the industrial application of human-engineered extracellular matrix (ECM) through the innovative approach of biological 3D printing, thereby redefining the manufacturing paradigm for cell-grade materials. Its technology holds significant transformative potential for regenerative medicine, particularly in the field of consumer healthcare. We are confident that the company, leveraging its technological leadership, will accelerate the global accessibility of cell-grade materials for users globally.

In Future：Innovation leads medical printing ecosystem upgrade

“With 25 years of persistent dedication, we have always believed that biological 3D printing technology will reshape the landscape of regenerative medicine, with human-engineered ECM serving as the key breakthrough,” stated the Huamei BioTech team. Following this round of financing, the company will continue to focus on the iteration of its core technologies, further expanding its global leading position in the field of 3D printed human-engineered ECM. Aligned with the national strategy for biomanufacturing under the “15th Five-Year Plan,” Huamei BioTech aims to advance China’s biomanufacturing industry from “technology leadership” to “value leadership,” securing a pivotal voice for China in the global multibillion-dollar regenerative materials market. The company is committed to providing core technological support for the pursuit of human vitality, health, and longevity.

Editor: Li Chen

E: lichen@3dzyk.com